20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10653 | c-met-IN-1 | c-Met/HGFR | |
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity. | |||
T8409 | SYN1143 | RON-IN-1,AMG-1 | c-Met/HGFR |
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively. | |||
T4332 | c-Kit-IN-1 | PDGFR inhibitor 1,DCC-2618 | c-Met/HGFR , c-Kit |
c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM). | |||
T13194 | CSF1R-IN-2 | c-Fms , c-Met/HGFR , Src | |
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively). | |||
T11162 | EGFR-IN-8 | EGFR , c-Met/HGFR | |
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC. | |||
T80874 | VEGFR-2/c-Met-IN-1 | VEGFR | |
VEGFR-2/c-Met-IN-1 is a dual inhibitor targeting VEGFR-2 and c-Met with respective IC50 values of 138 nM and 74 nM, demonstrating antitumor activity [1]. | |||
T72407 | c-Met/MEK1/Flt-3-IN-1 | ||
Antiproliferative Against-3 (comp 33) demonstrates significant activity against Hela (IC 50 = 0.21 µM), A549 (IC 50 = 0.39 µM), and MCF-7 (IC 50 = 0.33 µM) cell lines. Additionally, it induces apoptosis in a dose-depende... | |||
T63544 | RIPK3-IN-1 | ||
RIPK3-IN-1 is a type II RIPK3DFG-out site inhibitor (IC50: 9.1 nM) that inhibits RIPK1 (IC50: 5.5 μM) and RIPK2 (IC50>10 μM). RIPK3-IN-1 is a c-Met kinase inhibitor (IC50: 1.1 μM). | |||
T2668 | JNK-IN-8 | JNK Inhibitor XVI | JNK , c-Kit |
JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM). The selectivity is higher 10-fold than MNK2, Fms and no inhibition of Met, c-Kit, PDGFRβ in A375 cell line. | |||
T4349 | Sitravatinib | MG516,MGCD516 | Discoidin Domain Receptor (DDR) , VEGFR , FLT , Trk receptor , TAM Receptor , c-Kit , Ephrin Receptor |
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl. | |||
T5S1331 | Herbacetin | c-Met/HGFR , Akt | |
1. Herbacetin induces apoptosis in HepG2 cells, by ROS and PI3K/Akt pathway. 2. Herbacetin suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation. | |||
T64080 | c-Met-IN-12 | ||
c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to ... | |||
T79142 | c-Met-IN-17 | c-Met/HGFR | |
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1] | |||
T78934 | c-Met-IN-18 | c-Met/HGFR | |
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively. It is utilized in research pertaining to c-MET-driven cancer... | |||
T64185 | TAM&Met-IN-1 | ||
TAM&Met-IN-1 is a potent inhibitor of TAM and c-Met, acting on AXL (IC50: 6.1 nM), MER (IC50: 13.2 nM) and TYRO3 (IC50: 21.6 nM). TAM&Met-IN-1 can be used in anticancer studies. | |||
T72978 | c-Met-IN-16 | ||
c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research . | |||
T79715 | c-Met-IN-19 | c-Met/HGFR | |
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549, HT-29, SGC-7901, and MDA-MB-231, with IC50 values of 0.25, 0... | |||
T63901 | Axl-IN-8 | ||
Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM). | |||
T80885 | Val-Cit-amide-Cbz-N(Me)-Maytansine | ||
Val-Cit-amide-Cbz-N(Me)-Maytansine is a molecule that functions both as an antibody and a bispecific antigen-binding entity, targeting the hepatocyte growth factor receptor c-Met (MET), and is used in the formulation of ... | |||
T83557 | (3S,4S)-Tivantinib | ARQ 198,(3S,4S)-ARQ 197 | |
(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in the pathogenesis of non-small cell lung cancer (NSCLC) [1]. |